NewsBenzinga이뮤론, ‘사이언티픽 리포트’에 하루 한 번 복용하는 경구용 트래블란의 2상 임상시험 데이터 발표; 위약 대비 ETEC 도전 관련 이상반응 50% 통계적으로 유의미하게 감소 이뮤론, ‘사이언티픽 리포트’에 하루 한 번 복용하는 경구용 트래블란의 2상 임상시험 데이터 발표; 위약 대비 ETEC 도전 관련 이상반응 50% 통계적으로 유의미하게 감소 Benzinga 2026.10.13 10:06 (GMT+0) Open on Benzinga Other news China's Central Bank: Do a Good Job in Financial Support for the Development of the AI Industry Peter Schiff Says AI Could Rewrite the Rules of Starting a Business: ‘Don’t Look for a Job’ Hunterbrook Report: Digital Realty’s $3 Billion Georgia Data Center Hits Toxic Roadblock After White Phosphorus Found At Former Army Dump Pre-market US stocks: Memory sector broadly higher, Micron Technology (MU.O) up 2.40% AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease Musk announces he will gift one SpaceX share to every child in the U.S. next year
Hunterbrook Report: Digital Realty’s $3 Billion Georgia Data Center Hits Toxic Roadblock After White Phosphorus Found At Former Army Dump
